Search - tctmd.com

Displaying 61 - 80 of 82

Sort: Relevancy | Date

AHA Scientific Statement Aims to Raise Awareness of Chagas Disease and Risk for Cardiomyopathy

News Daily News

AHA Scientific Statement Aims to Raise Awareness of Chagas Disease and Risk for Cardiomyopathy

August 24, 2018

TCTMD’s Top 10 Most Popular Stories for February 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2018

March 01, 2018

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

News Conference News AHA 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

November 22, 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

November 16, 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

News Conference News AHA 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

November 15, 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

News Conference News AHA 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

Michael O'Riordan

November 13, 2017

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Presentation AHA 2017

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Presenter: Akihiko Nogami

November 13, 2017

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

News Conference News ACC 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

March 21, 2017

AHA Wades Into Conversation Over Periprocedural Use of Non-Vitamin K Antagonist Oral Anticoagulants

News Daily News

AHA Wades Into Conversation Over Periprocedural Use of Non-Vitamin K Antagonist Oral Anticoagulants

Yael L. Maxwell

February 13, 2017

News Conference News AHA 2016

误诊 NOAC 在日常实践中很常见，并对中风和出血有影响

November 21, 2016

News Conference News AHA 2016

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

November 21, 2016

News Conference News AHA 2016

Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias

November 21, 2016

News Conference News AHA 2016

亚临床型房颤常见于老年无症状患者

November 18, 2016

News Conference News AHA 2016

Subclinical A-fib Common in Older, Asymptomatic Patients

November 18, 2016

News Conference News AHA 2016

La FA Subclínica es Común en Pacientes Asintomáticos de Mayor Edad

November 18, 2016

News Conference News AHA 2016

Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results

November 15, 2016

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.